Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone plus ADT and radiotherapy in very high-risk locally advanced prostate cancer
2014-002071-29Phase 2Terminated
- Sponsor
- USL8
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone, prednisone and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by USL8. Primary endpoint: Event-free survival. Started Nov 2014; status: terminated.
02
Drugs
abirateroneprednisonebicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-002071-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002071-29.